Phathom Pharmaceuticals (PHAT) Net Income towards Common Stockholders (2018 - 2026)
Phathom Pharmaceuticals (PHAT) reported Net Income towards Common Stockholders of -$29.5 million for Q1 2026, up 68.67% year-over-year from -$17.5 million in Q1 2025, and down 39.71% quarter-over-quarter from -$21.1 million in Q4 2025.
Phathom Pharmaceuticals (PHAT) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$29.5 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$29.5 million, up 68.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$156.3 million (up 54.8% YoY), and the FY2025 annual result was -$221.1 million, up 33.88% from the prior year.
- Net Income towards Common Stockholders retreated to -$29.5 million in Q1 2026 per PHAT's latest filing, from -$21.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$21.1 million in Q4 2025 and troughed at -$94.3 million in Q1 2025.
- A 5-year average of -$57.9 million and a median of -$51.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 123.2% in 2024, then surged 71.62% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$55.0 million in 2022, then plunged by 44.76% to -$79.6 million in 2023, then grew by 6.36% to -$74.5 million in 2024, then surged by 71.62% to -$21.1 million in 2025, then sank by 39.71% to -$29.5 million in 2026.
- Business Quant data shows PHAT's Net Income towards Common Stockholders at -$29.5 million in Q1 2026, -$21.1 million in Q4 2025, and -$30.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | -29.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.54 Mn |
| Dec 31, 2025 | -21.14 Mn |
| Sep 30, 2025 | -29.97 Mn |
| Jun 30, 2025 | -75.66 Mn |
| Mar 31, 2025 | -94.29 Mn |
| Dec 31, 2024 | -74.50 Mn |
| Sep 30, 2024 | -85.57 Mn |
| Jun 30, 2024 | -91.44 Mn |
| Mar 31, 2024 | -82.81 Mn |
| Dec 31, 2023 | -79.56 Mn |
| Sep 30, 2023 | -43.05 Mn |
| Jun 30, 2023 | -40.97 Mn |
| Mar 31, 2023 | -37.83 Mn |
| Dec 31, 2022 | -54.96 Mn |
| Sep 30, 2022 | -51.08 Mn |
| Jun 30, 2022 | -50.92 Mn |
| Mar 31, 2022 | -40.66 Mn |
| Dec 31, 2021 | -35.81 Mn |
| Sep 30, 2021 | -34.61 Mn |
| Jun 30, 2021 | -36.56 Mn |